IE00BQ70R696
IE00BQ70R696
Invesco NASDAQ Biotech UCITS ETF Acc
Loading chart...
Holdings & Portfolio Structure
Holdings as of 09/13/2026Detailed breakdown of ETF components
Synthetic Replication Note (Swap ETF)
Synthetic (Swap)The reported holdings, valuation ratios (P/E, etc.), and analyst estimates reflect the fund's underlying collateral/substitute basket, not the actual composition of the tracked index.
This ETF replicates index returns using financial derivatives (total return swaps) with counterparty banks. For regulatory reasons, the fund maintains a physical collateral basket which often consists of completely different securities than the benchmark index. While price performance accurately tracks the benchmark, fundamentals, sector weights, and individual holdings represent this collateral basket.
All Holdings
| 1 |  | Vertex Pharmaceuticals Incorpor | Healthcare | Biotechnology | 115,31 Mrd. € | 8.16% | 29.71 | 25.23 | 9.77% | 6.38 | 10.26 | 23.86 | 49.17 | 2.03% | FY Cur +10.45% (16) Q Cur +11.16% (13) FY Next +9.84% (16) Q Next +3.20% (14) | FY Cur -11.12% (16) Q Cur -115.38% (13) FY Next +23.62% (16) Q Next +721.48% (14) |
| 2 |  | Amgen Inc. | Healthcare | Drug Manufacturers - General | 200,18 Mrd. € | 8.06% | 25.77 | 16.94 | 490.28% | 19.19 | 5.89 | 15.27 | 25.94 | 3.85% | FY Cur +5.98% (31) Q Cur +5.15% (24) FY Next +3.62% (31) Q Next +2.19% (23) | FY Cur +5.47% (33) Q Cur +2.21% (27) FY Next +6.29% (33) Q Next +0.71% (27) |
| 3 |  | Gilead Sciences, Inc. | Healthcare | Drug Manufacturers - General | 167,29 Mrd. € | 7.64% | - | 15.24 | 223.47% | 15.86 | 6.15 | 13.95 | 19.19 | 5.21% | FY Cur +4.36% (25) Q Cur +0.17% (20) FY Next +6.57% (24) Q Next +4.63% (17) | FY Cur -105.06% (27) Q Cur -11.85% (22) FY Next +2503.59% (26) Q Next -0.10% (20) |
| 4 |  | Regeneron Pharmaceuticals, Inc. | Healthcare | Biotechnology | 68,6 Mrd. € | 5.53% | 18.46 | 12.11 | 8.54% | 2.36 | 4.95 | 14.58 | 25.07 | 3.99% | FY Cur +20.31% (25) Q Cur +20.96% (19) FY Next +7.56% (23) Q Next +8.04% (18) | FY Cur +27.56% (27) Q Cur +35.49% (22) FY Next -10.42% (9) Q Next +11.61% (21) |
| 5 |  | Moderna, Inc. | Healthcare | Biotechnology | 80,17 Mrd. € | 3.67% | - | -50.70 | 19.04% | 13.28 | 40.32 | -34.08 | 300.18 | 0.33% | FY Cur +8.09% (21) Q Cur -12.17% (14) FY Next +16.07% (19) Q Next -24.31% (13) | FY Cur -15.53% (21) Q Cur -149.18% (15) FY Next +43.00% (20) Q Next -37.19% (14) |
| 6 |  | Revolution Medicines, Inc. | Healthcare | Biotechnology | 36,3 Mrd. € | 2.92% | - | -33.17 | 45.68% | 15.60 | - | -23.22 | - | -1.75% | FY Cur +0.00% (23) Q Cur +0.00% (20) FY Next +567.30% (23) Q Next +573.29% (19) | FY Cur -61.64% (23) Q Cur -48.32% (21) FY Next +40.52% (23) Q Next +17.56% (21) |
| 7 |  | Alnylam Pharmaceuticals, Inc. | Healthcare | Biotechnology | 27,79 Mrd. € | 2.24% | 37.83 | 18.73 | 220.62% | 22.98 | 6.48 | 28.19 | 114.66 | 0.87% | FY Cur +47.50% (26) Q Cur +14.73% (20) FY Next +26.78% (26) Q Next +9.32% (20) | FY Cur +73.90% (14) Q Cur -21.24% (14) FY Next +40.62% (14) Q Next +19.29% (14) |
| 8 |  | Biogen Inc. | Healthcare | Drug Manufacturers - General | 29,76 Mrd. € | 2.15% | 40.09 | 13.65 | 44.33% | 1.77 | 3.33 | 11.71 | 26.32 | 3.80% | FY Cur +5.66% (32) Q Cur +4.00% (26) FY Next +2.04% (32) Q Next -1.22% (25) | FY Cur -17.96% (33) Q Cur -57.93% (26) FY Next +31.94% (33) Q Next +61.72% (26) |
| 9 |  | Illumina, Inc. | Healthcare | Diagnostics & Research | 37,49 Mrd. € | 2.06% | 51.90 | 45.46 | 89.04% | 14.80 | 9.35 | 35.77 | 52.66 | 1.90% | FY Cur +6.48% (19) Q Cur +6.34% (17) FY Next +6.46% (19) Q Next +5.84% (16) | FY Cur +10.69% (21) Q Cur +1.31% (19) FY Next +14.20% (21) Q Next +13.15% (18) |
| 10 |  | Roivant Sciences Ltd. | Healthcare | Biotechnology | 22,85 Mrd. € | 1.99% | - | -20.63 | 2.18% | 6.05 | 3398.72 | -15.92 | - | -4.40% | FY Cur +530.75% (12) Q Cur +136.10% (11) FY Next +685.92% (12) Q Next +231.50% (11) | FY Cur -46.66% (3) Q Cur -63.34% (3) FY Next -8.69% (3) Q Next +8.42% (3) |
| 11 |  | Insmed Incorporated | Healthcare | Biotechnology | 19,61 Mrd. € | 1.87% | - | 127.76 | 97.65% | 28.99 | 19.31 | -27.07 | - | -2.60% | FY Cur +197.18% (22) Q Cur +250.76% (20) FY Next +59.72% (21) Q Next +12.87% (19) | FY Cur +75.47% (18) Q Cur +78.64% (17) FY Next +150.00% (18) Q Next +14.14% (17) |
| 12 |  | argenx SE | Healthcare | Biotechnology | 46,31 Mrd. € | 1.84% | 31.19 | 23.76 | 0.56% | 153.25 | 9.76 | 790.35 | 68.11 | 1.47% | FY Cur +48.20% (4) Q Cur +43.13% (2) FY Next +21.64% (4) Q Next +8.94% (2) | FY Cur -4.56% (4) Q Cur -288.71% (2) FY Next +85.91% (3) Q Next +189.72% (1) |
| 13 |  | Royalty Pharma plc | Healthcare | Biotechnology | 29,36 Mrd. € | 1.76% | 30.28 | 9.82 | 91.58% | 3.71 | 12.97 | 23.18 | - | -3.63% | FY Cur +7.71% (5) Q Cur +8.70% (4) FY Next +8.97% (5) Q Next +6.38% (3) | FY Cur +10.18% (6) Q Cur +0.62% (6) FY Next +8.98% (6) Q Next +28.87% (5) |
| 14 |  | Incyte Corporation | Healthcare | Biotechnology | 20,4 Mrd. € | 1.67% | 14.37 | 12.91 | 0.60% | 3.57 | 3.93 | 9.45 | 19.36 | 5.16% | FY Cur +15.49% (23) Q Cur +7.95% (20) FY Next +5.35% (23) Q Next +3.42% (19) | FY Cur -52.32% (19) Q Cur -262.56% (16) FY Next +169.37% (21) Q Next +152.33% (17) |
| 15 |  | United Therapeutics Corporation | Healthcare | Drug Manufacturers - Specialty & Generic | 21,02 Mrd. € | 1.45% | 19.67 | 16.25 | - | 3.66 | 7.47 | 13.49 | 42.28 | 2.37% | FY Cur -0.74% (14) Q Cur -1.87% (13) FY Next +12.09% (14) Q Next +2.94% (13) | FY Cur -6.10% (14) Q Cur -13.24% (14) FY Next +15.44% (14) Q Next +10.83% (14) |
| 16 |  | Guardant Health, Inc. | Healthcare | Diagnostics & Research | 20,06 Mrd. € | 1.43% | - | -405.82 | - | - | 19.00 | -53.09 | 844.66 | 0.12% | FY Cur +38.24% (25) Q Cur +32.20% (21) FY Next +35.29% (25) Q Next +5.32% (20) | FY Cur +19.43% (21) Q Cur +19.79% (17) FY Next +71.86% (19) Q Next +11.31% (17) |
| 17 |  | Viatris Inc. | Healthcare | Drug Manufacturers - Specialty & Generic | 18,08 Mrd. € | 1.29% | - | 6.60 | 95.53% | 1.40 | 1.37 | 7.49 | 7.57 | 13.21% | FY Cur +3.44% (9) Q Cur +1.07% (9) FY Next +1.68% (9) Q Next -2.18% (9) | FY Cur +7.07% (11) Q Cur -3.98% (10) FY Next +6.30% (11) Q Next -8.06% (10) |
| 18 |  | Medpace Holdings, Inc. | Healthcare | Diagnostics & Research | 15,25 Mrd. € | 1.13% | 35.94 | 31.69 | 33.22% | 39.37 | 6.14 | 26.94 | 33.47 | 2.99% | FY Cur +12.72% (13) Q Cur +8.27% (11) FY Next +6.33% (13) Q Next +0.89% (11) | FY Cur +15.94% (10) Q Cur +15.57% (8) FY Next +9.03% (10) Q Next +5.05% (8) |
| 19 |  | Ascendis Pharma A/S | Healthcare | Biotechnology | 13,46 Mrd. € | 1.09% | 17.57 | 23.84 | 31.33% | 9.31 | 14.41 | 54.14 | 1181.06 | 0.08% | FY Cur +90.14% (18) Q Cur +70.76% (16) FY Next +47.13% (18) Q Next +12.98% (16) | FY Cur - (5) Q Cur - (3) FY Next -24.82% (5) Q Next +23.49% (3) |
| 20 |  | Neurocrine Biosciences, Inc. | Healthcare | Drug Manufacturers - Specialty & Generic | 12,92 Mrd. € | 1.06% | 20.89 | 11.99 | 12.50% | 3.92 | 4.29 | 15.80 | 22.69 | 4.41% | FY Cur +36.44% (25) Q Cur +31.46% (23) FY Next +16.61% (24) Q Next +3.90% (22) | FY Cur +59.85% (16) Q Cur +25.70% (16) FY Next +16.28% (16) Q Next +3.92% (16) |
| 21 |  | Jazz Pharmaceuticals plc | Healthcare | Biotechnology | 12,65 Mrd. € | 1.02% | 14.97 | 8.46 | 91.83% | 2.95 | 3.08 | 8.64 | 9.92 | 10.08% | FY Cur +10.61% (21) Q Cur +6.94% (18) FY Next +5.76% (21) Q Next +2.65% (18) | FY Cur +158.32% (19) Q Cur -61.86% (19) FY Next +19.25% (19) Q Next +109.81% (19) |
| 22 |  | Exelixis, Inc. | Healthcare | Biotechnology | 13,24 Mrd. € | 0.98% | 18.88 | 14.01 | 9.00% | 8.08 | 6.09 | 13.67 | 20.05 | 4.99% | FY Cur +10.09% (17) Q Cur +8.69% (15) FY Next +13.62% (16) Q Next +2.17% (15) | FY Cur +16.36% (10) Q Cur +14.96% (9) FY Next +19.25% (10) Q Next -0.25% (9) |
| 23 |  | BridgeBio Pharma, Inc. | Healthcare | Biotechnology | 11,4 Mrd. € | 0.96% | - | 2261.25 | - | - | 17.92 | -32.53 | - | -2.51% | FY Cur +104.49% (19) Q Cur +124.02% (17) FY Next +65.30% (18) Q Next +17.06% (17) | FY Cur +31.71% (8) Q Cur +12.65% (7) FY Next +101.12% (7) Q Next +30.05% (7) |
| 24 |  | Summit Therapeutics Inc. | Healthcare | Biotechnology | 12,52 Mrd. € | 0.89% | - | -20.40 | 3.24% | 22.15 | - | -14.89 | - | -1.00% | FY Cur +0.00% (15) Q Cur +0.00% (14) FY Next +1326.97% (15) Q Next +5415.31% (14) | FY Cur +20.61% (11) Q Cur +7.43% (12) FY Next -1.83% (10) Q Next -15.50% (11) |
| 25 |  | Halozyme Therapeutics, Inc. | Healthcare | Biotechnology | 11,19 Mrd. € | 0.86% | 32.29 | 10.39 | 1517.69% | 87.70 | 7.53 | 13.72 | 37.15 | 2.69% | FY Cur +33.93% (8) Q Cur +38.31% (6) FY Next +10.74% (8) Q Next +10.76% (6) | FY Cur +109.98% (6) Q Cur +35.12% (6) FY Next +22.02% (5) Q Next +12.69% (6) |
Results: 246
USWeight 8.16%
Market Cap €115.31B
P/E 29.7
Fwd P/E 25.2
USWeight 8.06%
Market Cap €200.18B
P/E 25.8
Fwd P/E 16.9
USWeight 7.64%
Market Cap €167.29B
P/E -
Fwd P/E 15.2
USWeight 5.53%
Market Cap €68.6B
P/E 18.5
Fwd P/E 12.1
USWeight 3.67%
Market Cap €80.17B
P/E -
Fwd P/E -50.7
USWeight 2.92%
Market Cap €36.3B
P/E -
Fwd P/E -33.2
USWeight 2.24%
Market Cap €27.79B
P/E 37.8
Fwd P/E 18.7
USWeight 2.15%
Market Cap €29.76B
P/E 40.1
Fwd P/E 13.6
USWeight 2.06%
Market Cap €37.49B
P/E 51.9
Fwd P/E 45.5
GBWeight 1.99%
Market Cap €22.85B
P/E -
Fwd P/E -20.6
USWeight 1.87%
Market Cap €19.61B
P/E -
Fwd P/E 127.8
NLWeight 1.84%
Market Cap €46.31B
P/E 31.2
Fwd P/E 23.8
USWeight 1.76%
Market Cap €29.36B
P/E 30.3
Fwd P/E 9.8
USWeight 1.67%
Market Cap €20.4B
P/E 14.4
Fwd P/E 12.9
USWeight 1.45%
Market Cap €21.02B
P/E 19.7
Fwd P/E 16.3
USWeight 1.43%
Market Cap €20.06B
P/E -
Fwd P/E -405.8
USWeight 1.29%
Market Cap €18.08B
P/E -
Fwd P/E 6.6
USWeight 1.13%
Market Cap €15.25B
P/E 35.9
Fwd P/E 31.7
DKWeight 1.09%
Market Cap €13.46B
P/E 17.6
Fwd P/E 23.8
USWeight 1.06%
Market Cap €12.92B
P/E 20.9
Fwd P/E 12.0
IEWeight 1.02%
Market Cap €12.65B
P/E 15.0
Fwd P/E 8.5
USWeight 0.98%
Market Cap €13.24B
P/E 18.9
Fwd P/E 14.0
USWeight 0.96%
Market Cap €11.4B
P/E -
Fwd P/E 2261.2
USWeight 0.89%
Market Cap €12.52B
P/E -
Fwd P/E -20.4
USWeight 0.86%
Market Cap €11.19B
P/E 32.3
Fwd P/E 10.4
Results 1 - 25 of 246
Per page:
Page 1 / 10